These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A, Morra E, Colombi M, Callea V, Pogliani E, Ilariucci F, Luminari S, Morel P, Merlini G, Gobbi P. J Clin Oncol; 2005 Jul 20; 23(21):4662-8. PubMed ID: 16034042 [Abstract] [Full Text] [Related]
25. Malignant transformation in IgM monoclonal gammopathy of undetermined significance. Montoto S, Rozman M, Rosiñol L, Nadal E, Giné E, Aymerich M, Ferrer A, Esteve J, Bosch F, López-Guillermo A, Bladé J, Montserrat E. Semin Oncol; 2003 Apr 20; 30(2):178-81. PubMed ID: 12720132 [Abstract] [Full Text] [Related]
27. The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS. Klein CJ, Moon JS, Mauermann ML, Zeldenrust SR, Wu Y, Dispenzieri A, Dyck PJ. Can J Neurol Sci; 2011 Mar 20; 38(2):289-95. PubMed ID: 21320835 [Abstract] [Full Text] [Related]
29. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, Corso A, Orlandi E, Bonfichi M, Gotti M, Pascutto C, Mangiacavalli S, Croci G, Fiaccadori V, Morello L, Guerrera ML, Paulli M, Cazzola M. Blood; 2013 Mar 28; 121(13):2522-8. PubMed ID: 23355535 [Abstract] [Full Text] [Related]
32. Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Martín-Jiménez P, García-Sanz R, Balanzategui A, Alcoceba M, Ocio E, Sanchez ML, González M, San Miguel J. Haematologica; 2007 May 28; 92(5):635-42. PubMed ID: 17488687 [Abstract] [Full Text] [Related]
33. [Epidemiology of monoclonal gammopathy in a general hospital and a university internal medicine department]. Decaux O, Rodon P, Ruelland A, Estepa L, Leblay R, Grosbois B. Rev Med Interne; 2007 Oct 28; 28(10):670-6. PubMed ID: 17566610 [Abstract] [Full Text] [Related]
34. Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy. Morra E, Cesana C, Klersy C, Varettoni M, Cavanna L, Canesi B, Tresoldi E, Barbarano L, Lazzarino M, Hematology/Oncology Studies and Trials (HOST) Group, Italy. Semin Oncol; 2003 Apr 28; 30(2):172-7. PubMed ID: 12720131 [Abstract] [Full Text] [Related]
37. Familial Waldenstrom's macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies--A population-based study from northern Sweden. Brandefors L, Kimby E, Lundqvist K, Melin B, Lindh J. Acta Oncol; 2016 Apr 28; 55(1):91-8. PubMed ID: 26559865 [Abstract] [Full Text] [Related]
38. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P, Morra E, Cortelazzo S, Bettini R, Merlini G. Clin Cancer Res; 2005 Mar 01; 11(5):1786-90. PubMed ID: 15756000 [Abstract] [Full Text] [Related]